What We're Reading: Page 129
Industry reads hand-picked by our editors
Mar 23, 2022
Mar 22, 2022
-
Financial Times
Finance, culture, talent: why Europe struggles to commercialise its biotech expertise
-
Reuters
Former Takeda vaccine chief to lead new COVID antiviral venture Aerium
-
Evaluate Vantage
Biohaven's high-risk bet
-
Bloomberg
Pfizer to Sell Up to 4 Million Doses of Covid Drug Paxlovid to 95 Nations
Mar 21, 2022
-
The Guardian
Can we vaccinate against Epstein-Barr, the virus you didn’t know you had?
-
Nature
The future of research collaborations involving Russia
-
The New York Times
‘He Goes Where the Fire Is’: A Virus Hunter in the Wuhan Market
-
Bloomberg
To Ensure Medical Breakthroughs, Give ARPA-H Autonomy
Mar 18, 2022
-
The Wall Street Journal
Ivermectin Didn’t Reduce Covid-19 Hospitalizations in Largest Trial to Date
-
STAT
Lawmakers face off about the future of the FDA’s accelerated approval pathway
-
The Financial Times
AstraZeneca prepared to ditch effort to secure US approval for Covid vaccine
-
The New York Times
‘Stealth’ Omicron Is Stealthy No More: What’s Known About the BA.2 Variant
Mar 17, 2022
Mar 16, 2022
-
STAT
Gilead faces criticism for donations to lawmakers who backed 'Don't Say Gay' bill
-
Undark
The Worrying Murkiness of Institutional Biosafety Committees
-
The Wall Street Journal
Frazier Healthcare Partners Raises $986 Million Biotech Venture Fund
-
Scientific American
Tiny Antennas Made from DNA Light Up Protein Activity
Previous
